The FDA approved Bayer’s Lynkuet, a once‑daily non‑hormonal treatment targeting NK1 and NK3 receptors to reduce moderate‑to‑severe vasomotor symptoms of menopause. Approval was supported by three late‑stage trials demonstrating reductions in hot‑flash frequency and severity and benefits for sleep and quality of life. Bayer positions Lynkuet as a differentiated option versus existing non‑hormonal therapies that target NK3 only; the company highlighted rapid symptomatic relief observed in trials. The decision adds competition to Astellas’s Veozah and signals growing investor interest in menopause therapeutics. Commercial uptake and reimbursement dynamics will determine market penetration; prior launches in this class faced reimbursement headwinds and safety label changes, so Bayer will focus on payer engagement and prescriber education.